Form 10-Q Theravance Biopharma, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Theravance Biopharma (TBPH) Will Make VIBATIV Poster Presentation at ATS 2016
May 11, 2016 8:06 AM EDTTheravance Biopharma, Inc. (NASDAQ: TBPH) announced that new data on VIBATIV (telavancin), the Company's FDA-approved antibiotic, will be the focus of a poster presentation at the American Thoracic Society (ATS) 2016 International Conference. Researchers will present results from post hoc analyses of the previously completed Phase 3 ATTAIN (Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia) studies, registrational trials which supported the regulatory approval of telavancin (marketed as VIBATIV) for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). The ATS 2016 International Conference is being held in San Francisco on May 13-18, 2016.
The... More
